Autologous Dendritic Cell / Tumor Antigen (ADCTA) for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)

Condition:   Glioblastoma Multiforme Intervention:   Biological: Autologous Dendritic Cell/Tumor Antigen, ADCTA Sponsor:   Safe Save Medical Cell Sciences& Technology Co.,Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Immunotherapy | Research